Continued cannabis use at one year follow up is associated with elevated mood and lower global functioning in bipolar I disorder

BMC Psychiatry

Petter Andreas Ringen¹  Ole Andreas Andreassen³  Trine Vik Lagerberg³  Christine Demmo³  Sofie Ragnhild Aminoff²  Ingrid Melle³  Levi Roestad Kvitland³ 

[1]Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway

[2]Division of Mental Health Services, Department of Specialized Inpatient Treatment, Akershus University Hospital, Akershus, Norway

[3]NORMENT, KG Jebsen Center for Psychosis Research, Division of Mental Health and Addiction, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Norway TOP Study, Building 49, Oslo University Hospital, Ullevål, Kirkeveien 166, PO Box 4956 Nydalen, 0424, Oslo, Norway

关键词: Bipolar;    Cannabis;   

Others  :  1123292
DOI  :  10.1186/s12888-015-0389-x

 received in 2014-09-01, accepted in 2015-01-15,  发布年份 2015

【 摘 要 】

Background

There is limited knowledge about how environmental factors affect the course of bipolar disorder (BD). Cannabis has been proposed as a potential risk factor for poorer course of illness, but the role of cannabis use has not been studied in a first treatment BD I sample.

Methods

The present study examines the associations between course of illness in first treatment BD I and continued cannabis use, from baseline to one year follow up. Patients (N = 62) with first treatment DSM-IV BD I were included as part of the Thematically Organized Psychosis study (TOP), and completed interviews and self-report questionnaires at both baseline and follow up. Cannabis use within the last six months at baseline and use between baseline and follow up (“continued use”) was recorded.

Results

After controlling for confounders, continued cannabis use was significantly associated with elevated mood (YMRS) and inferior global functioning (GAF-F) at follow up. Elevated mood mediated the effect of cannabis use on global functioning.

Conclusions

These results suggest that cannabis use has clinical implications for the early course of BD by increasing mood level. More focus on reducing cannabis use in clinical settings seems to be useful for improving outcome in early phase of the disorder.

【 授权许可】

   
2015 Kvitland et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Ringen PA, Lagerberg TV, Birkenaes AB, Engn J, Faerden A, Jonsdottir H, et al.: Differences in prevalence and patterns of substance use in schizophrenia and bipolar disorder. Psychol Med 2008, 38(9):1241-9.
• [2]Najt P, Fusar-Poli P, Brambilla P: Co-occurring mental and substance abuse disorders: a review on the potential predictors and clinical outcomes. Psychiatry Res 2011, 186(2–3):159-64.
• [3]Cerullo MA, Strakowski SM: The prevalence and significance of substance use disorders in bipolar type I and II disorder. SubstAbuse Treat Prev Policy 2007, 2:29. BioMed Central Full Text
• [4]Tohen M, Vieta E, Gonzalez-Pinto A, Reed C, Lin D: Baseline characteristics and outcomes in patients with first episode or multiple episodes of acute mania. J Clin Psychiatry 2010, 71(3):255-61.
• [5]Strakowski SM, DelBello MP, Fleck DE, Arndt S: The impact of substance abuse on the course of bipolar disorder. Biol Psychiatry 2000, 48(6):477-85.
• [6]Baethge C, Hennen J, Khalsa HM, Salvatore P, Tohen M, Baldessarini RJ: Sequencing of substance use and affective morbidity in 166 first-episode bipolar I disorder patients. Bipolar Disord 2008, 10(6):738-41.
• [7]Heffner JL, DelBello MP, Anthenelli RM, Fleck DE, Adler CM, Strakowski SM: Cigarette smoking and its relationship to mood disorder symptoms and co-occurring alcohol and cannabis use disorders following first hospitalization for bipolar disorder. Bipolar Disord 2012, 14(1):99-108.
• [8]Etain B, Lajnef M, Bellivier F, Mathieu F, Raust A, Cochet B, et al.: Clinical expression of bipolar disorder type I as a function of age and polarity at onset: convergent findings in samples from France and the United States. J Clin Psychiatry 2012, 73(4):e561-6.
• [9]Larsson S, Lorentzen S, Mork E, Barrett EA, Steen NE, Lagerberg TV, et al.: Age at onset of bipolar disorder in a Norwegian catchment area sample. J Affect Disord 2010, 124(1–2):174-7.
• [10]Lagerberg TV, Sundet K, Aminoff SR, Berg AO, Ringen PA, Andreassen OA, et al.: Excessive cannabis use is associated with earlier age at onset in bipolar disorder. Eur Arch Psychiatry Clin Neurosci 2011, 261(6):397-405.
• [11]Lagerberg TV, Kvitland LR, Aminoff SR, Aas M, Ringen PA, Andreassen OA, et al.: Indications of a dose–response relationship between cannabis use and age at onset in bipolar disorder. Psychiatry Res 2014, 215(1):101-4.
• [12]Braga RJ, Burdick KE, Derosse P, Malhotra AK: Cognitive and clinical outcomes associated with cannabis use in patients with bipolar I disorder. Psychiatry Res 2012, 200(2–3):242-5.
• [13]De Hert M, Wampers M, Jendricko T, Franic T, Vidovic D, De VN, et al.: Effects of cannabis use on age at onset in schizophrenia and bipolar disorder. Schizophr Res 2011, 126(1–3):270-6.
• [14]Henquet C, Krabbendam L, de Graaf R, Ten Have M, Van Os J: Cannabis use and expression of mania in the general population. J Affect Disord 2006, 95(1–3):103-10.
• [15]Ostacher MJ, Perlis RH, Nierenberg AA, Calabrese J, Stange JP, Salloum I, et al.: Impact of substance use disorders on recovery from episodes of depression in bipolar disorder patients: prospective data from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatr 2010, 167(3):289-97.
• [16]Azorin JM, Kaladjian A, Adida M, Fakra E, Hantouche E, Lancrenon S: Baseline and prodromal characteristics of first- versus multiple-episode mania in a French cohort of bipolar patients. Eur Psychiatry 2012, 27(8):557-62.
• [17]Aas M, Etain B, Bellivier F, Henry C, Lagerberg T, Ringen A, et al.: Additive effects of childhood abuse and cannabis abuse on clinical expressions of bipolar disorders. Psychol Med 2013, 13:1-10.
• [18]van Rossum I, Boomsma M, Tenback D, Reed C, van Os J: Does cannabis use affect treatment outcome in bipolar disorder? A longitudinal analysis. J Nerv Ment Dis 2009, 197(1):35-40.
• [19]Lev-Ran S, Le Foll B, McKenzie K, George TP, Rehm J: Bipolar disorder and co-occurring cannabis use disorders: Characteristics, co-morbidities and clinical correlates. Psychiatry Res 2013, 209(3):459-65.
• [20]Zorrilla I, Aguado J, Haro JM, Barbeito S, Lopez ZS, Ortiz A, et al.: Cannabis and bipolar disorder: does quitting cannabis use during manic/mixed episode improve clinical/functional outcomes? Acta Psychiatr Scand 2015, 131(2):100-10.
• [21]Gonzalez-Pinto A, Reed C, Novick D, Bertsch J, Haro JM: Assessment of medication adherence in a cohort of patients with bipolar disorder. Pharmacopsychiatry 2010, 43(7):263-70.
• [22]Strakowski SM, DelBello MP, Fleck DE, Adler CM, Anthenelli RM, Keck PE Jr, et al.: Effects of co-occurring cannabis use disorders on the course of bipolar disorder after a first hospitalization for mania. Arch Gen Psychiatry 2007, 64(1):57-64.
• [23]American Psychiatric Association: Diagnostic and statistical manual of mental disorders: DSM-IV. American Psychiatric Association, Washington; 1994.
• [24]First M, Spitzer RL, Gibbon M, Williams J: Structural Clinical Interview for DSM-IV Axis I Disorders - Clinical Version (SCID-CV). American Psychiatric Press, Washington DC; 1997.
• [25]Endicott J, Spitzer RL, Fleiss JL, Cohen J: The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 1976, 33(6):766-71.
• [26]Pedersen G, Hagtvet KA, Karterud S: Generalizability studies of the Global Assessment of Functioning-Split version. Compr. Psychiatry 2007, 48(1):88-94.
• [27]Stone MH: Exploratory psychotherapy in schizophrenia-spectrum patients. A reevaluation in the light of long-term follow-up of schizophrenic and borderline patients. Bull Menninger Clin 1986, 50(3):287-306.
• [28]Rush AJ, Giles DE, Schlesser MA, Fulton CL, Weissenburger J, Burns C: The Inventory for Depressive Symptomatology (IDS): preliminary findings. Psychiatry Res 1986, 18(1):65-87.
• [29]Young RC, Biggs JT, Ziegler VE, Meyer DA: A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978, 133:429-35.
• [30]Kay SR, Fiszbein A, Opler LA: The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987, 13(2):261-76.
• [31]Cannon-Spoor HE, Potkin SG, Wyatt RJ: Measurement of premorbid adjustment in chronic schizophrenia. Schizophr Bull 1982, 8(3):470-84.
• [32]Shrout PE, Fleiss JL: Intraclass correlations: uses in assessing rater reliability. Psychol Bull 1979, 86(2):420-8.
• [33]Bahorik AL, Newhill CE, Eack SM: Characterizing the Longitudinal Patterns of Substance Use Among Individuals Diagnosed with Serious Mental Illness after Psychiatric Hospitalization. Addiction 2013, 108(7):1259-69.
• [34]Baethge C, Baldessarini RJ, Khalsa HM, Hennen J, Salvatore P, Tohen M: Substance abuse in first-episode bipolar I disorder: indications for early intervention. Am J Psychiatr 2005, 162(5):1008-10.
• [35]Ayesa-Arriola R, Rodriguez-Sanchez JM, Perez-Iglesias R, Gonzalez-Blanch C, Pardo-Garcia G, Tabares-Seisdedos R, et al.: The relevance of cognitive, clinical and premorbid variables in predicting functional outcome for individuals with first-episode psychosis: a 3 year longitudinal study. Psychiatry Res 2013, 209(3):302-8.
• [36]Ringen PA, Melle I, Berg AO, Agartz I, Spigset O, Simonsen C, et al.: Cannabis use and premorbid functioning as predictors of poorer neurocognition in schizophrenia spectrum disorder. Schizophr Res 2013, 143(1):84-9.
• [37]Hall W, Degenhardt L: Adverse health effects of non-medical cannabis use. Lancet 2009, 374(9698):1383-91.
• [38]Greydanus DE, Hawver EK, Greydanus MM, Merrick J: Marijuana: Current Concepts. Frontiers Public Health 2013, 1:42.
• [39]Lev-Ran S, Roerecke M, Le Foll B, George TP, McKenzie K, Rehm J: The association between cannabis use and depression: a systematic review and meta-analysis of longitudinal studies. Psychol Med 2013, 24:1-14.
• [40]Gonzalez-Pinto A, Alberich S, Barbeito S, Gutierrez M, Vega P, Ibanez B, et al.: Cannabis and first-episode psychosis: different long-term outcomes depending on continued or discontinued use. Schizophr Bull 2011, 37(3):631-9.
• [41]Gonzalez-Pinto A, Vega P, Ibanez B, Mosquera F, Barbeito S, Gutierrez M, et al.: Impact of cannabis and other drugs on age at onset of psychosis. J Clin Psychiatry 2008, 69(8):1210-6.
• [42]Kuepper R, Morrison PD, van Os J, Murray RM, Kenis G, Henquet C: Does dopamine mediate the psychosis-inducing effects of cannabis? A review and integration of findings across disciplines. Soc Psychiatry Psychiatr Epidemiol 2010, 121(1–3):107-17.
• [43]Large M, Sharma S, Compton MT, Slade T, Nielssen O: Cannabis use and earlier onset of psychosis: a systematic meta-analysis. Arch Gen Psychiatry 2011, 68(6):555-61.
• [44]Batalla A, Garcia-Rizo C, Castellvi P, Fernandez-Egea E, Yucel M, Parellada E, et al.: Screening for substance use disorders in first-episode psychosis: Implications for readmission. Schizophr Res 2013, 146(1-3):125-31.
• [45]Denis C, Fatseas M, Beltran V, Bonnet C, Picard S, Combourieu I, et al.: Validity of the self-reported drug use section of the Addiction Severity Index and associated factors used under naturalistic conditions. Subst Use Misuse 2012, 47(4):356-63.
• [46]Hjorthoj CR, Hjorthoj AR, Nordentoft M: Validity of Timeline Follow-Back for self-reported use of cannabis and other illicit substances–systematic review and meta-analysis. Addict Behav 2012, 37(3):225-33.